Calamos Advisors LLC Buys 5,661 Shares of Allergan plc (NYSE:AGN)

Share on StockTwits

Calamos Advisors LLC raised its holdings in Allergan plc (NYSE:AGN) by 1.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 328,598 shares of the company’s stock after purchasing an additional 5,661 shares during the period. Calamos Advisors LLC owned 0.10% of Allergan worth $55,300,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Strs Ohio increased its stake in shares of Allergan by 8.9% in the third quarter. Strs Ohio now owns 659,441 shares of the company’s stock worth $110,977,000 after purchasing an additional 54,100 shares in the last quarter. Whittier Trust Co. increased its stake in shares of Allergan by 0.5% in the third quarter. Whittier Trust Co. now owns 53,319 shares of the company’s stock worth $8,973,000 after purchasing an additional 267 shares in the last quarter. Whittier Trust Co. of Nevada Inc. increased its stake in shares of Allergan by 2.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 18,629 shares of the company’s stock worth $3,135,000 after purchasing an additional 425 shares in the last quarter. Moody National Bank Trust Division increased its stake in shares of Allergan by 0.4% in the third quarter. Moody National Bank Trust Division now owns 24,411 shares of the company’s stock worth $4,108,000 after purchasing an additional 93 shares in the last quarter. Finally, Tuttle Tactical Management purchased a new position in shares of Allergan in the third quarter worth about $929,000. Hedge funds and other institutional investors own 80.52% of the company’s stock.

Several equities analysts have recently weighed in on AGN shares. Cantor Fitzgerald lifted their target price on shares of Allergan from $125.00 to $165.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. TheStreet raised shares of Allergan from a “d+” rating to a “c” rating in a research note on Friday, July 12th. Mizuho cut shares of Allergan from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $171.00 to $188.00 in a research note on Wednesday, June 26th. Svb Leerink reaffirmed a “market perform” rating and set a $188.00 price objective (down previously from $217.00) on shares of Allergan in a research note on Thursday, July 18th. Finally, Wells Fargo & Co reaffirmed an “outperform” rating and set a $184.00 price objective (up previously from $176.00) on shares of Allergan in a research note on Monday, September 30th. One analyst has rated the stock with a sell rating, sixteen have given a hold rating and six have given a buy rating to the company. Allergan has a consensus rating of “Hold” and a consensus price target of $179.15.

Allergan stock traded up $0.88 during mid-day trading on Monday, hitting $174.48. 565,974 shares of the company traded hands, compared to its average volume of 2,180,941. Allergan plc has a one year low of $114.27 and a one year high of $191.72. The stock has a market cap of $56.60 billion, a price-to-earnings ratio of 10.45, a price-to-earnings-growth ratio of 2.04 and a beta of 1.65. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.91 and a current ratio of 1.03. The stock has a fifty day moving average price of $166.16 and a 200-day moving average price of $152.51.

Allergan (NYSE:AGN) last announced its earnings results on Tuesday, August 6th. The company reported $4.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.34 by $0.04. The business had revenue of $4.09 billion during the quarter, compared to analyst estimates of $3.93 billion. Allergan had a negative net margin of 54.25% and a positive return on equity of 8.73%. Allergan’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the previous year, the business posted $4.42 earnings per share. Sell-side analysts predict that Allergan plc will post 16.68 EPS for the current year.

Allergan Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Featured Story: Conference Calls and Individual Investors

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analyzing NeXt Innovation  and Putnam Municipal Opportunities Trust
Analyzing NeXt Innovation and Putnam Municipal Opportunities Trust
$749.39 Million in Sales Expected for Visteon Corp  This Quarter
$749.39 Million in Sales Expected for Visteon Corp This Quarter
Reviewing Polarityte  and Aerie Pharmaceuticals
Reviewing Polarityte and Aerie Pharmaceuticals
Insider Buying: Centrica PLC  Insider Purchases £150.10 in Stock
Insider Buying: Centrica PLC Insider Purchases £150.10 in Stock
Luke Savage Purchases 10,000 Shares of Numis Co. PLC  Stock
Luke Savage Purchases 10,000 Shares of Numis Co. PLC Stock
Insider Selling: Paragon Banking Group PLC  Insider Sells £143,100 in Stock
Insider Selling: Paragon Banking Group PLC Insider Sells £143,100 in Stock


 
© 2006-2019 Zolmax.